Your Article Summary
Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome
Clinical Cancer Research, 06/03/09
Ma W et al. - Measuring plasma chymotrypsin-like activity may provide a powerful biomarker for risk stratification in patients with AML and advanced-stage MDS, including those with normal karyotype.
Related Articles
Prognostic molecular markers in myelodysplastic syndromes
Expert Review of Hematology, 10/22/09
Relevance Score: 68%
Hematopoiesis-related microRNA expression in myelodysplastic syndromes
Leukemia and Lymphoma, 11/06/09
Relevance Score: 67%
Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome
International Journal of Laboratory Hematology, 10/28/09
Relevance Score: 66%
Accelerated cellular senescence in myelodysplastic syndrome
Experimental Hematology, 10/22/09
Relevance Score: 66%
Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression
Blood, 10/09/09
Relevance Score: 66%
Today in Leukemia/Lymphoma...keeping you current
Receive free subspecialty "5-minute updates" via email
microRNAs in acute myeloid leukemia: Expression patterns, correlations with genetic and clinical parameters, and prognostic significance
Genes, Chromosomes and Cancer, 12/19/09
Cytogenetics of long-term survivors of ETV6-RUNX1 fusion positive acute lymphoblastic leukemia
Genes, Chromosomes and Cancer, 12/19/09
Primary cutaneous diffuse large B cell lymphoma relapsed solely as a huge lung tumor mimicking a primary pulmonary lymphoma
International Journal of Hematology, 12/17/09
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Telomere shortening and chromosomal instability in myelodysplastic syndromes
Genes, Chromosomes and Cancer, 12/19/09
Living with multiple myeloma: experiences of patients and their informal caregivers
Supportive Care in Cancer, 12/17/09
Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
Annals of Hematology, 12/17/09

See Latest Articles